Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 64

1.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Chui Ming GC, Tun SBB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2019 May;11(5). pii: e10666. doi: 10.15252/emmm.201910666. No abstract available.

2.

BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changes.

Lee VK, Hosking BM, Holeniewska J, Kubala EC, Lundh von Leithner P, Gardner PJ, Foxton RH, Shima DT.

Diabetologia. 2018 Nov;61(11):2422-2432. doi: 10.1007/s00125-018-4696-x. Epub 2018 Aug 9.

3.

Sox7 promotes high-grade glioma by increasing VEGFR2-mediated vascular abnormality.

Kim IK, Kim K, Lee E, Oh DS, Park CS, Park S, Yang JM, Kim JH, Kim HS, Shima DT, Kim JH, Hong SH, Cho YH, Kim YH, Park JB, Koh GY, Ju YS, Lee HK, Lee S, Kim I.

J Exp Med. 2018 Mar 5;215(3):963-983. doi: 10.1084/jem.20170123. Epub 2018 Feb 14.

4.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. No abstract available.

5.

Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases.

Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G.

EMBO Mol Med. 2016 Nov 2;8(11):1265-1288. doi: 10.15252/emmm.201505889. Print 2016 Nov. Erratum in: EMBO Mol Med. 2019 May;11(5):.

6.

Distal retinal ganglion cell axon transport loss and activation of p38 MAPK stress pathway following VEGF-A antagonism.

Foxton R, Osborne A, Martin KR, Ng YS, Shima DT.

Cell Death Dis. 2016 May 5;7:e2212. doi: 10.1038/cddis.2016.110.

7.

Novel CCR3 Antagonists Are Effective Mono- and Combination Inhibitors of Choroidal Neovascular Growth and Vascular Permeability.

Nagai N, Ju M, Izumi-Nagai K, Robbie SJ, Bainbridge JW, Gale DC, Pierre E, Krauss AH, Adamson P, Shima DT, Ng YS.

Am J Pathol. 2015 Sep;185(9):2534-49. doi: 10.1016/j.ajpath.2015.04.029. Epub 2015 Jul 16.

8.

Differential apicobasal VEGF signaling at vascular blood-neural barriers.

Hudson N, Powner MB, Sarker MH, Burgoyne T, Campbell M, Ockrim ZK, Martinelli R, Futter CE, Grant MB, Fraser PA, Shima DT, Greenwood J, Turowski P.

Dev Cell. 2014 Sep 8;30(5):541-52. doi: 10.1016/j.devcel.2014.06.027. Epub 2014 Aug 28.

9.

Spontaneous CNV in a novel mutant mouse is associated with early VEGF-A-driven angiogenesis and late-stage focal edema, neural cell loss, and dysfunction.

Nagai N, Lundh von Leithner P, Izumi-Nagai K, Hosking B, Chang B, Hurd R, Adamson P, Adamis AP, Foxton RH, Ng YS, Shima DT.

Invest Ophthalmol Vis Sci. 2014 May 20;55(6):3709-19. doi: 10.1167/iovs.14-13989.

10.

A2E induces IL-1ß production in retinal pigment epithelial cells via the NLRP3 inflammasome.

Anderson OA, Finkelstein A, Shima DT.

PLoS One. 2013 Jun 28;8(6):e67263. doi: 10.1371/journal.pone.0067263. Print 2013.

11.

VEGF-A is necessary and sufficient for retinal neuroprotection in models of experimental glaucoma.

Foxton RH, Finkelstein A, Vijay S, Dahlmann-Noor A, Khaw PT, Morgan JE, Shima DT, Ng YS.

Am J Pathol. 2013 Apr;182(4):1379-90. doi: 10.1016/j.ajpath.2012.12.032. Epub 2013 Feb 12.

12.

Assessing a novel depot delivery strategy for noninvasive administration of VEGF/PDGF RTK inhibitors for ocular neovascular disease.

Robbie SJ, Lundh von Leithner P, Ju M, Lange CA, King AG, Adamson P, Lee D, Sychterz C, Coffey P, Ng YS, Bainbridge JW, Shima DT.

Invest Ophthalmol Vis Sci. 2013 Feb 27;54(2):1490-500. doi: 10.1167/iovs.12-10169.

PMID:
23385800
13.

Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.

Harris S, Craze M, Newton J, Fisher M, Shima DT, Tozer GM, Kanthou C.

PLoS One. 2012;7(5):e35231. doi: 10.1371/journal.pone.0035231. Epub 2012 May 2.

14.

Forkhead box N4 (Foxn4) activates Dll4-Notch signaling to suppress photoreceptor cell fates of early retinal progenitors.

Luo H, Jin K, Xie Z, Qiu F, Li S, Zou M, Cai L, Hozumi K, Shima DT, Xiang M.

Proc Natl Acad Sci U S A. 2012 Feb 28;109(9):E553-62. doi: 10.1073/pnas.1115767109. Epub 2012 Feb 8.

15.

Delivery of anti-angiogenic molecular therapies for retinal disease.

Anderson OA, Bainbridge JW, Shima DT.

Drug Discov Today. 2010 Apr;15(7-8):272-82. doi: 10.1016/j.drudis.2010.02.004. Epub 2010 Feb 23. Review.

PMID:
20184967
16.

The heparin-binding domain confers diverse functions of VEGF-A in development and disease: a structure-function study.

Krilleke D, Ng YS, Shima DT.

Biochem Soc Trans. 2009 Dec;37(Pt 6):1201-6. doi: 10.1042/BST0371201.

PMID:
19909247
17.

Delta-like 4 is indispensable in thymic environment specific for T cell development.

Hozumi K, Mailhos C, Negishi N, Hirano K, Yahata T, Ando K, Zuklys S, Holländer GA, Shima DT, Habu S.

J Exp Med. 2008 Oct 27;205(11):2507-13. doi: 10.1084/jem.20080134. Epub 2008 Sep 29.

18.

Blood vessel maturation and response to vascular-disrupting therapy in single vascular endothelial growth factor-A isoform-producing tumors.

Tozer GM, Akerman S, Cross NA, Barber PR, Björndahl MA, Greco O, Harris S, Hill SA, Honess DJ, Ireson CR, Pettyjohn KL, Prise VE, Reyes-Aldasoro CC, Ruhrberg C, Shima DT, Kanthou C.

Cancer Res. 2008 Apr 1;68(7):2301-11. doi: 10.1158/0008-5472.CAN-07-2011.

19.

Simultaneous but not prior inhibition of VEGF165 enhances the efficacy of photodynamic therapy in multiple models of ocular neovascularization.

Ju M, Mailhos C, Bradley J, Dowie T, Ganley M, Cook G, Calias P, Lange N, Adamis AP, Shima DT, Robinson GS.

Invest Ophthalmol Vis Sci. 2008 Feb;49(2):662-70. doi: 10.1167/iovs.07-0195.

PMID:
18235012
20.

RGS5 expression is a quantitative measure of pericyte coverage of blood vessels.

Mitchell TS, Bradley J, Robinson GS, Shima DT, Ng YS.

Angiogenesis. 2008;11(2):141-51. Epub 2007 Nov 25.

PMID:
18038251
21.

Molecular mapping and functional characterization of the VEGF164 heparin-binding domain.

Krilleke D, DeErkenez A, Schubert W, Giri I, Robinson GS, Ng YS, Shima DT.

J Biol Chem. 2007 Sep 21;282(38):28045-56. Epub 2007 Jul 10.

22.

Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury.

Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, Akita J, Samuelsson SJ, Robinson GS, Adamis AP, Shima DT.

Am J Pathol. 2007 Jul;171(1):53-67.

23.

Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration.

Zuluaga MF, Mailhos C, Robinson G, Shima DT, Gurny R, Lange N.

Invest Ophthalmol Vis Sci. 2007 Apr;48(4):1767-72.

PMID:
17389510
24.

Erythropoietin promotes survival of retinal ganglion cells in DBA/2J glaucoma mice.

Zhong L, Bradley J, Schubert W, Ahmed E, Adamis AP, Shima DT, Robinson GS, Ng YS.

Invest Ophthalmol Vis Sci. 2007 Mar;48(3):1212-8.

PMID:
17325165
25.

Targeted deletion of p97 (VCP/CDC48) in mouse results in early embryonic lethality.

Müller JM, Deinhardt K, Rosewell I, Warren G, Shima DT.

Biochem Biophys Res Commun. 2007 Mar 9;354(2):459-65. Epub 2007 Jan 8.

PMID:
17239345
26.

Inhibitory effect of an antibody to cryptic collagen type IV epitopes on choroidal neovascularization.

Jo N, Ju M, Nishijima K, Robinson GS, Adamis AP, Shima DT, Mailhos C.

Mol Vis. 2006 Oct 26;12:1243-9.

27.

An in vitro assay reveals a role for the diaphragm protein PV-1 in endothelial fenestra morphogenesis.

Ioannidou S, Deinhardt K, Miotla J, Bradley J, Cheung E, Samuelsson S, Ng YS, Shima DT.

Proc Natl Acad Sci U S A. 2006 Nov 7;103(45):16770-5. Epub 2006 Oct 30.

28.

Proceedings of the Third International Symposium on Retinopathy of Prematurity: an update on ROP from the lab to the nursery (November 2003, Anaheim, California).

Lutty GA, Chan-Ling T, Phelps DL, Adamis AP, Berns KI, Chan CK, Cole CH, D'Amore PA, Das A, Deng WT, Dobson V, Flynn JT, Friedlander M, Fulton A, Good WV, Grant MB, Hansen R, Hauswirth WW, Hardy RJ, Hinton DR, Hughes S, McLeod DS, Palmer EA, Patz A, Penn JS, Raisler BJ, Repka MX, Saint-Geniez M, Shaw LC, Shima DT, Smith BT, Smith LE, Tahija SG, Tasman W, Trese MT.

Mol Vis. 2006 May 23;12:532-80.

29.

Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization.

Jo N, Mailhos C, Ju M, Cheung E, Bradley J, Nishijima K, Robinson GS, Adamis AP, Shima DT.

Am J Pathol. 2006 Jun;168(6):2036-53.

30.

Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease.

Ng EW, Shima DT, Calias P, Cunningham ET Jr, Guyer DR, Adamis AP.

Nat Rev Drug Discov. 2006 Feb;5(2):123-32. Review.

PMID:
16518379
31.

A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Lee JH, Canny MD, De Erkenez A, Krilleke D, Ng YS, Shima DT, Pardi A, Jucker F.

Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):18902-7. Epub 2005 Dec 15.

32.

VEGF function in vascular pathogenesis.

Ng YS, Krilleke D, Shima DT.

Exp Cell Res. 2006 Mar 10;312(5):527-37. Epub 2005 Dec 5. Review.

PMID:
16330026
33.

The role of vascular endothelial growth factor in ocular health and disease.

Adamis AP, Shima DT.

Retina. 2005 Feb-Mar;25(2):111-8. Review.

PMID:
15689799
34.

Vascular endothelial growth factor controls neuronal migration and cooperates with Sema3A to pattern distinct compartments of the facial nerve.

Schwarz Q, Gu C, Fujisawa H, Sabelko K, Gertsenstein M, Nagy A, Taniguchi M, Kolodkin AL, Ginty DD, Shima DT, Ruhrberg C.

Genes Dev. 2004 Nov 15;18(22):2822-34.

35.

VEGF164(165) as the pathological isoform: differential leukocyte and endothelial responses through VEGFR1 and VEGFR2.

Usui T, Ishida S, Yamashiro K, Kaji Y, Poulaki V, Moore J, Moore T, Amano S, Horikawa Y, Dartt D, Golding M, Shima DT, Adamis AP.

Invest Ophthalmol Vis Sci. 2004 Feb;45(2):368-74.

PMID:
14744874
36.

VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.

Ishida S, Usui T, Yamashiro K, Kaji Y, Amano S, Ogura Y, Hida T, Oguchi Y, Ambati J, Miller JW, Gragoudas ES, Ng YS, D'Amore PA, Shima DT, Adamis AP.

J Exp Med. 2003 Aug 4;198(3):483-9.

37.

Mutations in dynein link motor neuron degeneration to defects in retrograde transport.

Hafezparast M, Klocke R, Ruhrberg C, Marquardt A, Ahmad-Annuar A, Bowen S, Lalli G, Witherden AS, Hummerich H, Nicholson S, Morgan PJ, Oozageer R, Priestley JV, Averill S, King VR, Ball S, Peters J, Toda T, Yamamoto A, Hiraoka Y, Augustin M, Korthaus D, Wattler S, Wabnitz P, Dickneite C, Lampel S, Boehme F, Peraus G, Popp A, Rudelius M, Schlegel J, Fuchs H, Hrabe de Angelis M, Schiavo G, Shima DT, Russ AP, Stumm G, Martin JE, Fisher EM.

Science. 2003 May 2;300(5620):808-12.

38.

Spatially restricted patterning cues provided by heparin-binding VEGF-A control blood vessel branching morphogenesis.

Ruhrberg C, Gerhardt H, Golding M, Watson R, Ioannidou S, Fujisawa H, Betsholtz C, Shima DT.

Genes Dev. 2002 Oct 15;16(20):2684-98.

39.

VE-PTP and VE-cadherin ectodomains interact to facilitate regulation of phosphorylation and cell contacts.

Nawroth R, Poell G, Ranft A, Kloep S, Samulowitz U, Fachinger G, Golding M, Shima DT, Deutsch U, Vestweber D.

EMBO J. 2002 Sep 16;21(18):4885-95. Erratum in: EMBO J. 2005 Sep 7;24(17):3158.

40.

Sequential SNARE disassembly and GATE-16-GOS-28 complex assembly mediated by distinct NSF activities drives Golgi membrane fusion.

Muller JM, Shorter J, Newman R, Deinhardt K, Sagiv Y, Elazar Z, Warren G, Shima DT.

J Cell Biol. 2002 Jun 24;157(7):1161-73. Epub 2002 Jun 17.

41.

Centrosome disorganization in fibroblast cultures derived from R6/2 Huntington's disease (HD) transgenic mice and HD patients.

Sathasivam K, Woodman B, Mahal A, Bertaux F, Wanker EE, Shima DT, Bates GP.

Hum Mol Genet. 2001 Oct 1;10(21):2425-35.

PMID:
11689489
42.

Golgi clusters and vesicles mediate mitotic inheritance independently of the endoplasmic reticulum.

Jokitalo E, Cabrera-Poch N, Warren G, Shima DT.

J Cell Biol. 2001 Jul 23;154(2):317-30.

43.

Vascular developmental biology: getting nervous.

Shima DT, Mailhos C.

Curr Opin Genet Dev. 2000 Oct;10(5):536-42.

PMID:
10980432
44.

Synergistic roles for Pim-1 and c-Myc in STAT3-mediated cell cycle progression and antiapoptosis.

Shirogane T, Fukada T, Muller JM, Shima DT, Hibi M, Hirano T.

Immunity. 1999 Dec;11(6):709-19.

45.

An NSF function distinct from ATPase-dependent SNARE disassembly is essential for Golgi membrane fusion.

Müller JM, Rabouille C, Newman R, Shorter J, Freemont P, Schiavo G, Warren G, Shima DT.

Nat Cell Biol. 1999 Oct;1(6):335-40.

PMID:
10559959
46.

Segregation of COPI-rich and anterograde-cargo-rich domains in endoplasmic-reticulum-to-Golgi transport complexes.

Shima DT, Scales SJ, Kreis TE, Pepperkok R.

Curr Biol. 1999 Jul 29-Aug 12;9(15):821-4.

47.

Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188.

Carmeliet P, Ng YS, Nuyens D, Theilmeier G, Brusselmans K, Cornelissen I, Ehler E, Kakkar VV, Stalmans I, Mattot V, Perriard JC, Dewerchin M, Flameng W, Nagy A, Lupu F, Moons L, Collen D, D'Amore PA, Shima DT.

Nat Med. 1999 May;5(5):495-502. No abstract available.

PMID:
10229225
48.
49.

Inheritance of the mammalian Golgi apparatus during the cell cycle.

Cabrera-Poch N, Pepperkok R, Shima DT.

Biochim Biophys Acta. 1998 Aug 14;1404(1-2):139-51. Review.

50.

Supplemental Content

Loading ...
Support Center